Dr. Hongru Li | Brain Metastasis | Best Researcher Award

Profile

ORCID

Education

Dr. Hongru Li’s academic foundation is firmly rooted in medicine and specialized respiratory science. He earned his Doctor of Medicine degree at Fujian Medical University, where he developed his core clinical knowledge and interest in pulmonary health. To deepen his expertise, he pursued postgraduate studies in respiratory medicine at Fujian Medical University, gaining hands-on exposure to advanced diagnostic and therapeutic approaches in pulmonary and critical care. His academic journey culminated with a PhD in Respiratory Medicine from Southern Medical University in Guangzhou, where he focused on molecular mechanisms of lung cancer progression and metastasis. His doctoral research provided a solid grounding in translational medicine, integrating clinical insights with cellular and molecular biology. This comprehensive educational background has enabled him to pursue a career balancing patient care with high-impact research, positioning him as a leader in respiratory medicine, oncology, and translational research with a strong focus on innovation and clinical application.

Experience

Dr. Hongru Li has accumulated extensive clinical and academic experience at Fujian Provincial Hospital, where he has advanced through progressive leadership roles in respiratory and critical care medicine. Starting as a resident doctor, he gained experience in managing complex respiratory cases, developing proficiency in critical care interventions. He then served as an attending doctor, where he refined his clinical judgment and mentored junior staff. His expertise led to his appointment as Associate Chief Physician, where he oversaw specialized clinical programs and research initiatives. Currently, as Chief Physician, Dr. Li leads the Department of Respiratory and Critical Care Medicine, managing advanced patient care, research collaborations, and clinical training. His responsibilities span from clinical decision-making to developing research projects funded by provincial and national agencies. With deep involvement in translational research, he bridges laboratory discoveries with real-world patient care, positioning him as both a skilled clinician and an innovative medical researcher.

Awards and Honors

Dr. Hongru Li has been recognized for his exceptional contributions to clinical medicine, research innovation, and academic excellence. Early in his career, he received the Excellent Graduate Award and Excellent Postgraduate Award from Fujian Medical University, reflecting his academic dedication and professional promise. His trajectory of excellence was further reinforced with the prestigious Outstanding Youth Respiratory Scholar Award for Clinical Innovation in China, acknowledging his groundbreaking research and leadership in respiratory medicine. These honors underscore his commitment to advancing lung cancer research, patient care, and translational medicine. His ability to secure competitive research funding and lead innovative studies further reflects his recognition as a trusted expert in his field. In addition, his patents and numerous peer-reviewed publications highlight the impact of his scientific contributions. These accolades collectively demonstrate not only his academic excellence but also his role as a leading physician-researcher shaping the future of respiratory and oncology medicine.

Research Focus

Dr. Hongru Li’s research centers on the molecular mechanisms driving lung cancer progression and metastasis, with particular emphasis on brain and bone metastases in non-small cell lung cancer. He explores signaling pathways, genetic susceptibility, and the role of lipids and ceramide metabolism in tumor development. His studies have investigated proteins such as livin, RPTOR, and ceramide synthase in regulating tumor proliferation, apoptosis, and metastatic spread. Through innovative approaches, including nanoliposome-based therapies, he seeks to inhibit cancer metastasis and improve treatment responses. He has also examined genetic polymorphisms and signaling cascades, such as the PI3K/AKT/mTOR and Wnt pathways, to understand cancer susceptibility and therapy resistance. His translational research aims to transform laboratory findings into clinical applications, offering new diagnostic biomarkers and therapeutic targets. Supported by national and provincial grants, his work significantly contributes to advancing precision medicine, improving survival, and developing novel treatment strategies for patients with lung cancer.

Publications

Title: KLF9 Inhibits Brain Metastasis of Non‐Small Cell Lung Cancer by Regulating Ceramide Synthase 1 Synthesis
Year: 2025

Title: Efficacy of Prophylactic Cranial Irradiation in Early to Mid-stage Small Cell Lung Cancer Patients in the Era of Magnetic Resonance Imaging
Year: 2024

Title: Development and validation of a nomogram model based on blood-based genomic mutation signature for predicting the risk of brain metastases in non-small cell lung cancer
Year: 2024

Title: Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic Klebsiella pneumoniae
Year: 2024

Title: Clinical application value of metagenome next-generation sequencing in pulmonary diffuse exudative lesions: a retrospective study
Year: 2024

Title: Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib
Year: 2024

Title: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding
Year: 2024

Conclusion

Dr. Hongru Li exemplifies the integration of clinical expertise and research innovation, dedicated to advancing respiratory and cancer medicine through groundbreaking studies, translational discoveries, and compassionate patient care.